The European Medicines Evaluations Agency on Monday announced that its scientific committee has rejected an application by Serono to market its anti-wasting drug Serostim to AIDS patients in Europe. The drug is approved for the treatment of AIDS-related wasting in the United States. In a statement, the agency said there was concern about the long-term safety of the medication and that long-term efficacy data also was lacking. Serostim is a recombinant human growth hormone that has been shown to increase muscle mass in those taking the medication.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes
These are some of his worst comments about LGBTQ+ people made by Charlie Kirk.